25.11.2010EasyMed Services to begin clinical with the University Hospital of GenevaYou are hereNewsEasyMed Services to begin clinical with the University Hospital of Geneva
The focus of this clinical trial is to determine the most reliable and cost-efficient solution to decrease the absenteeism rate of medical appointments in the Division of Primary Care Medicine. EasyMedMobile, the mobile telemedicine solution developed by the Company, will be tested with thousands of patients.
NHS Health & Care Innovation Expo11.09.2017A pavilion showcasing Swiss innovative companies with Personalised Medicine solutions at NHS Innovation & Care Expo...
Welcome To Health ValleyBuilding on skills honed over the centuries, western Switzerland has become a world leader in biotech.
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.